A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma-Reference-Cited by-同舟云学术

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

Published:2021-04-07 Issue:588 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Yang Weiqin¹^ORCID,Feng Yu¹^ORCID,Zhou Jingying¹²^ORCID,Cheung Otto Ka-Wing¹^ORCID,Cao Jianquan¹^ORCID,Wang Jing¹,Tang Wenshu¹^ORCID,Tu Yalin¹^ORCID,Xu Liangliang¹,Wu Feng²,Tan Zhiwu³⁴^ORCID,Sun Hanyong⁵,Tian Yuan⁶,Wong John⁷^ORCID,Lai Paul Bo-San⁷^ORCID,Chan Stephen Lam⁸⁹^ORCID,Chan Anthony Wing-Hung²^ORCID,Tan Patrick Boon-Ooi¹⁰¹¹¹²¹³¹⁴^ORCID,Chen Zhiwei³⁴^ORCID,Sung Joseph Jao-Yiu¹⁵¹⁶¹⁷^ORCID,Yip Kevin Yuk-Lap¹⁸,To Ka-Fai²⁹^ORCID,Cheng Alfred Sze-Lok¹^ORCID

Affiliation:

1. School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

2. Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

3. AIDS Institute, The University of Hong Kong, Hong Kong SAR 999077, China.

4. Department of Microbiology and Research Center for Infection and Immunity, The University of Hong Kong, Hong Kong SAR 999077, China.

5. Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

6. Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen 518061, China.

7. Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

8. Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

9. State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

10. Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.

11. Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore.

12. Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore 138672, Singapore.

13. SingHealth/Duke-NUS Institute of Precision Medicine, National Heart Centre Singapore, Singapore 169857, Singapore.

14. Cellular and Molecular Research, National Cancer Centre, Singapore 169610, Singapore.

15. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore.

16. State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

17. Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

18. Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

Abstract

HDAC8 inhibition elicits durable responses to immune checkpoint blockade by improving adaptive immune responses through enhancer reprogramming.

Funder

Terry Fox Foundation

Theme-based Research Scheme

University Grants Committee through the Collaborative Research Fund

The Focused Innovations Scheme-Scheme B from the Chinese University of Hong Kong

The Li Ka Shing Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference72 articles.

1. Elements of cancer immunity and the cancer–immune set point

2. Cancer immunotherapy using checkpoint blockade

3. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

4. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

5. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HDAC-targeting epigenetic modulators for cancer immunotherapy;European Journal of Medicinal Chemistry;2024-02

2. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients;2024-01-09

3. HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation;Cell Chemical Biology;2023-11

4. Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma;Seminars in Liver Disease;2023-11

5. Histone and Histone Acetylation-Related Alterations of Gene Expression in Uninvolved Psoriatic Skin and Their Effects on Cell Proliferation, Differentiation, and Immune Responses;International Journal of Molecular Sciences;2023-09-26